When the Doctor Asks, "What Do You Want to Do Next?"
If your husband has been diagnosed with metastatic castration-resistant prostate cancer (mCRPC), you may have already sat through many appointments. You have heard words like "progression" and "next line of therapy." You have watched him weigh options. A doctor may have mentioned Lu-177 PSMA therapy, or you found it online searching for answers.
This guide is for you - the partner or caregiver helping with this decision. It explains what Lu-177 PSMA therapy is, who it may help, what the decision-making process looks like, and how you can help your husband make an informed choice.
What Is Lu-177 PSMA Therapy?
Lu-177 PSMA therapy is a type of treatment called radioligand therapy. It uses a radioactive substance - lutetium-177 - attached to a molecule that seeks out a protein called PSMA (prostate-specific membrane antigen). PSMA is found in large amounts on the surface of most prostate cancer cells.
When the treatment is given through an IV infusion, the molecule travels through the bloodstream and binds to cancer cells that carry the PSMA protein. The radioactive lutetium hits those cancer cells with radiation while mostly protecting healthy tissue nearby.
The therapy is FDA-approved in the United States under the brand name Pluvicto. It may also be accessed internationally, including through nuclear medicine centers in India that serve international patients.
For many men with mCRPC - particularly those who have stopped responding to hormone therapy and have limited standard options - this therapy is worth exploring.
Understanding Your Role as a Caregiver in This Decision
Caregivers and partners play an important role in cancer treatment decisions. Research from the National Institutes of Health shows that most patients prefer to share treatment decisions with their partners, and this involvement may improve outcomes and wellbeing for both patient and caregiver.
Your job is to help him make a clear, informed choice. You can gather information, ask questions, and make sure his care team knows what matters most to him.
Who May Benefit from Lu-177 PSMA Therapy?
Lu-177 PSMA therapy is not for every man with prostate cancer. It is designed for men with mCRPC whose cancer has continued to grow despite prior treatments.
Men who may be considered for this therapy often share these characteristics:
- Their cancer has spread to bones, lymph nodes, or other sites (metastatic disease).
- The cancer has stopped responding to hormone therapy (castration-resistant).
- They have already tried at least one androgen receptor pathway inhibitor, such as enzalutamide or abiraterone.
- Their cancer cells carry the PSMA protein, confirmed by a PSMA PET scan.
- They are in reasonable enough physical condition to tolerate the treatment (performance status ECOG 0 to 2).
If this describes your husband, ask his oncology team whether an eligibility check makes sense. For details on how eligibility works, read: Am I a Candidate for Lu-177 PSMA Therapy? A Plain-Language Guide to Eligibility for Men with Metastatic Castration-Resistant Prostate Cancer.
The Eligibility Checklist: Questions to Bring to the Next Appointment
As a caregiver, you can help by asking the right questions. Below are standard criteria used for this therapy.
Has he had a PSMA PET scan?
This is often the critical first step. A PSMA PET scan uses a small amount of radioactive tracer to show whether the prostate cancer cells carry the PSMA protein. Without a positive result, Lu-177 PSMA therapy is generally not considered appropriate. If your husband has not had one, ask his oncologist whether he should get one at this stage.
For a full guide to what these scans involve and how to prepare, read: What Blood Tests and Scans Do You Need Before Lu-177 PSMA Treatment - A Patient Guide to Pre-Therapy Eligibility Screening.
Has hormone therapy stopped working?
The cancer must have progressed despite medical or surgical castration - typically confirmed by testosterone levels at or below 50 ng/mL alongside rising PSA or new lesions on imaging. If hormone therapy is still controlling the cancer, the timing may not be right yet for this therapy.
What prior treatments has he received?
The original FDA approval required at least one androgen receptor pathway inhibitor and one or two rounds of taxane-based chemotherapy. An expanded approval now allows access for some patients before chemotherapy, when delaying it is appropriate. Ask specifically whether your husband qualifies under either pathway, since this affects his options today.
What do his recent blood tests show?
He needs adequate bone marrow and kidney function before starting treatment. Blood counts - including white blood cells, platelets, and hemoglobin - need to be in safe ranges. His kidney function will be checked carefully. If recent labs show concerns in these areas, the care team may want to address those first before considering treatment.
How is he managing day to day?
Oncologists use a scale called ECOG performance status (scored 0 to 5) to assess how well a patient can carry out daily activities. Most programs consider patients who score 0, 1, or 2, meaning they can care for themselves and can get out of bed. If your husband is significantly weakened, ask whether this would affect eligibility - and whether he could improve his strength before evaluation.
What the Treatment Process Looks Like
Lu-177 PSMA therapy is given as an intravenous infusion - similar in some ways to a chemotherapy infusion, but the side effect profile and mechanism are quite different. Most programs involve up to six cycles, scheduled about six weeks apart. Each infusion takes roughly one to two hours at a nuclear medicine or radiology unit.
After each infusion, he'll get written radiation safety instructions. For a short period - usually a few days - he should limit close contact with others, especially pregnant women and young children. The care team will provide these instructions ahead of time so you can prepare.
Between cycles, blood tests and imaging check how he's responding and watch for side effects. This is an active, ongoing treatment program - not a single procedure.
For a detailed practical guide to what caregivers can expect during this time, including radiation safety at home and how to support your husband between cycles, read: What Should My Spouse or Caregiver Know About Helping Me Through Lu-177 PSMA Treatment for Metastatic Prostate Cancer.
What the Evidence Actually Shows - Explained Plainly
The most important clinical study for Lu-177 PSMA therapy is the VISION trial - a large, randomized phase 3 trial of 831 patients with PSMA-positive mCRPC. According to the National Cancer Institute, the key results showed:
- Median overall survival of 15.3 months with Lu-177 PSMA therapy added to standard care, compared to 11.3 months with standard care alone.
- Median radiographic progression-free survival (the time before imaging showed the cancer growing) of 8.7 months with the therapy, compared to 3.4 months without it.
These are not small differences in a disease setting where options are limited. Gains like these can mean extra time to adjust and try other options if needed.
The Prostate Cancer Foundation describes Lu-177 PSMA therapy as the first radioligand therapy to receive regulatory approval for advanced prostate cancer. It's a new type of treatment that works differently from chemotherapy or hormone therapy.
Keep in mind that trial results show medians - some patients did better than these numbers, and some did worse. No single data point can predict exactly what will happen for your husband. His cancer biology, prior treatment history, organ function, and overall health affect how he responds.
Honest Expectations: Benefits and Known Limitations
Understanding what to expect will help you support your husband better. Here is what the evidence shows:
- Lu-177 PSMA therapy may slow cancer growth and extend the time before disease progression.
- Many patients report meaningful improvement in bone pain during or after treatment.
- PSA levels may fall in patients who respond to the therapy, though PSA alone does not fully confirm a treatment response.
- The therapy is not a cure and does not eliminate cancer permanently in most patients.
- Not every patient responds. Some men see limited or no measurable benefit.
- The degree and duration of response vary considerably from person to person.
Talking openly with your husband about his hopes and what matters most to him is more valuable than any research.
Side Effects Your Husband May Experience
The most common side effects reported in clinical trials and post-approval studies include fatigue, dry mouth (because salivary glands carry some PSMA protein), nausea, decreased appetite, anemia, and reduced white blood cell and platelet counts. Most are manageable and don't require stopping treatment.
However, bone marrow and kidney function need close monitoring throughout the treatment course. The care team will check blood results regularly to catch any problems early.
Knowing about these possibilities in advance helps you prepare. You can have easy foods ready for low-appetite periods and know which symptoms need a call to the care team. Ask the team for a written list of warning signs and a direct contact number for urgent concerns.
What International Families Should Know About Accessing This Therapy
For families from the United Kingdom, Australia, Canada, the United States, Germany, the UAE, New Zealand, and other countries, India offers access to Lu-177 PSMA therapy at nuclear medicine centers that specialize in this therapy. Treatment is often available at significantly lower cost than in Western countries, with teams trained to help international patients.
The typical steps for international families include sharing medical records, scan reports, and treatment history for an initial remote eligibility review - no travel needed yet. If eligible, a remote consultation with the specialist team comes next to discuss timing and planning. Treatment cycles are then scheduled about six weeks apart, allowing many families to coordinate two or three cycles per trip and return home between visits.
A patient navigator can help you build a plan that fits your family's situation, including travel capacity, financial considerations, and coordination with your husband's home oncology team.
When to Talk to Your Doctor
If your husband's prostate cancer has stopped responding to hormone therapy, or if his current treatment is no longer controlling the disease, ask his oncologist specifically about PSMA PET scanning and eligibility for Lu-177 PSMA therapy. If this hasn't come up or your doctor dismisses it without a full explanation, ask for a referral to a nuclear medicine specialist or a second opinion from a center that specializes in this therapy.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
What is the first step if we think my husband might qualify for Lu-177 PSMA therapy?
The first step is a PSMA PET scan. This imaging test shows whether the cancer cells carry the PSMA protein that the therapy targets. Without a positive result, Lu-177 PSMA therapy is generally not considered appropriate. Ask his oncologist whether ordering this scan is right for his current stage of disease. If you are unsure how to interpret the results afterward, a specialist in nuclear medicine or radioligand therapy can help explain what they mean for eligibility.
Can I attend the treatment appointments with my husband?
In most centers, a companion is welcome for check-in and the waiting period. Policies about being present in the treatment room during the actual infusion vary by site. After each infusion, your husband will receive radiation safety instructions - this typically includes limiting close contact with others for a few days, particularly with pregnant women and young children. These precautions are time-limited and manageable with advance planning. The care team will give you specific written guidance so there are no surprises.
How will the doctors know if the treatment is working?
Response is tracked through a combination of PSA measurements, blood tests, and repeat imaging such as follow-up PSMA PET scans or CT scans. Some patients see their PSA rise before it begins to fall, which can be misleading after the first cycle. The care team will assess trends across multiple cycles and look at the full picture - not a single number - before drawing conclusions about whether the therapy is helping.
My husband's oncologist has not mentioned Lu-177 PSMA therapy. Should we bring it up?
Yes. It is appropriate to ask whether your husband has been evaluated for a PSMA PET scan and whether Lu-177 PSMA therapy is relevant at his current disease stage. If the oncologist is not familiar with radioligand therapy, asking for a referral to a nuclear medicine specialist or to a center with specific experience in this treatment is a reasonable request. Seeking a second opinion in advanced prostate cancer is common, widely accepted, and often opens up options that were not previously on the table.
What documents do we need to request an eligibility review?
For a specialist eligibility review, gather the most recent PSMA PET scan or Ga-68 PSMA PET-CT report, any previous PET-CT or bone scan reports, histopathology (biopsy) reports confirming the diagnosis, a full list of prior treatments including hormone therapy and any chemotherapy, and recent blood test results covering kidney function and a full blood count. Having these ready before contacting a specialist center makes the review faster and more thorough.